type 2 diabetes mellitus
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) patients with type 2 diabetes using sitagliptin (50mg, once daily) or vildagliptin(50mg, twice daily) for more than 3 months 2) HbA1c 5.8-7.9% (JDS), HbA1c 6.2-8.3%(NGSP) 3) written informed consent
Exclusion criteria
Exclusion criteria: 1) patients who received insulin injection therapy 2) severe hepatic dysfunction, renal dysfunction, heart failure 3) history of anaphylaxis of Sitagliptin or Vildagliptin, 4) pregnancy and lactation 5) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate changes in MAGE; mean amplitude of glycemic excursions before and after switching from sitagliptin to vildagliptin, and vice versa | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) M-value 2) fasting plasma glucose, HbA1c, glycoalbumin 3) beta cell function 4) changes in body weight, Body Mass Index, abdominal girth, blood pressure 5) several biomarkers | — |
Countries
Japan
Contacts
Hokkaido University Hospital Department of Medicine II